Vectormune FP ILT + AE

RSS

fowlpox, avian infectious laryngotracheitis vaccine (live, recombinant) and avian encephalomyelitis vaccine (live)

Authorised
This medicine is authorised for use in the European Union.

Overview

Vectormune FP ILT + AE is a veterinary vaccine used in chickens to reduce skin damage due to fowlpox (FP), to reduce the clinical signs and tracheal (windpipe) damage due to avian infectious laryngotracheitis (ILT) and to prevent loss of egg production due to avian encephalomyelitis (AE).

Vectormune FP ILT + AE contains the active substances live fowlpox virus which has been modified to produce certain proteins found in avian infectious laryngotracheitis virus and a specific strain of avian encephalomyelitis virus.

This EPAR was last updated on 09/09/2020

Authorisation details

Product details
Name
Vectormune FP ILT + AE
Agency product number
EMEA/V/C/005077
Active substance
live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rFP-LT) and avian encephalomyelitis virus, strain Calnek 1143 (AE)
International non-proprietary name (INN) or common name
fowlpox, avian infectious laryngotracheitis vaccine (live, recombinant) and avian encephalomyelitis vaccine (live)
Species
Chicken
Anatomical therapeutic chemical veterinary (ATCvet) codes
Not assigned
Publication details
Marketing-authorisation holder
CEVA-Phylaxia Co. Ltd.
Revision
1
Date of issue of marketing authorisation valid throughout the European Union
24/04/2020
Contact address

Szállás u. 5.
1107 Budapest
Hungary

Product information

29/06/2020 Vectormune FP ILT + AE - EMEA/V/C/005077 - IAIN/0001

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Immunologicals for aves

  • Live viral vaccines
  • Domestic fowl

Therapeutic indication

For active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

Assessment history

How useful was this page?

Add your rating